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Background: We aimed to investigate the prognostic value of two biomarkers of tissue inflammation, matrix
metalloproteinase-dependent degradation of C-reactive protein (CRPM) and connective tissue type I collagen
turnover (C1M), on the incidence and progression of radiographic osteoarthritis (OA) in the Rotterdam Study, a
prospective cohort. Moreover, the independent effect of these biomarkers with respect to the established
biomarkers of OA progression, like urinary type II collagen degradation (uCTX-II) and serum cartilage oligomeric
protein (COMP), was evaluated.
Methods: Serum levels of C1M, CRPM, COMP and CRP of 1335 participants aged >55 years were measured in
fasting serum using ELISA. The commercial ELISA detecting CTX-II was used in urine. Radiographs at baseline and
5-year follow-up were scored for OA stage by Kellgren-Lawrence grade. The associations between progression and
incidence of OA and the baseline biomarkers were examined using logistic regression and generalized estimating
equations adjusted for age, sex, BMI, and possible other confounders.
Results: The uCTX-II, COMP, and CRP concentrations were associated with the incidence and progression of OA.
Moreover, OA progression was positively associated with CRPM (OR = 1.3, p = 0.01) and CRP (OR = 1.3, p = 0.01)
levels with similar effect size as uCTX-II (OR = 1.3, p = 0.01) and COMP (OR = 1.2, p = 0.02). CRPM had prognostic
value for progression of OA independent from the uCTX-II and COMP.
Conclusions: Our study confirmed the associations between uCTX-II and COMP concentrations and OA progression.
Importantly, we showed for the first time that CRPM predicts the risk of OA progression independent of the established
biomarkers uCTX-II and COMP.
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Osteoarthritis (OA), the most common form of arthrop-
athy, is characterized by alteration of joint structure
including progressive cartilage destruction, synovial in-
flammation, and changes to the subchondral bone [1].
The etiology of OA is not well understood although the
knowledge in this respect has accumulated during the* Correspondence: j.vanmeurs@erasmusmc.nl
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mechanisms [1], altered lipid metabolism [2] and inflam-
mation [3] might also be important drivers of the mo-
lecular mechanism underlying OA.
It is clear that OA is heterogeneous in its etiology and
disease course. Recent efforts are now focused on
identifying subgroups of patients with distinct disease
pathology, which will allow the development of new
targeted therapies [1]. Circulating biochemical markers
(biomarkers) have the potential to serve as a measure
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that can predict the course of OA. Up to now, only
urinary C-terminal telopeptide of collagen type II
(uCTX-II) and serum cartilage oligomeric protein
(COMP) (both markers of cartilage and bone metab-
olism) have shown discriminative ability for diagnosis
and prognosis of OA [4–10].
Compared to rheumatoid arthritis (RA) or seronega-
tive spondyloarthritis, inflammation is less prominent in
OA. There is no marked infiltration of inflammatory
cells into joint tissues, and the synovial fluid usually con-
tains few neutrophils [11]. C-reactive protein (CRP), a
systemic biomarker for inflammation, has been shown to
be elevated in some OA patients yet the evidence is con-
flicting [12]. Recent studies have suggested that local in-
flammation plays a prominent role in the pathogenesis,
symptoms, and progression of OA [3, 13, 14]. Recently,
a newly developed CRP measure was described. Matrix
metalloproteinase (MMP)-dependent degradation of CRP
(CRPM) can be measured in serum to quantify CRP frag-
ments released from the inflamed tissue, after CRP has
been synthesized in the liver and deposited in the joint
and degraded by the proteolytic burden [15]. It has been
shown that MMP-degraded CRP provides a more discrim-
inative diagnostic potential compared to that of full-length
CRP in ankylosing spondylitis (AS) patients [16].
Synovial inflammation (synovitis) is a common charac-
teristic of inflammatory OA and is believed to stimulate
the connective tissue turnover. Type I collagen, the most
abundant structural collagen of the human body, is a
collagen of the connective tissue, including the synovial
membrane. The collagen biomarker C1M is a measure
of MMP-driven soft tissue destruction [17]. In a recent
study among RA patients, C1M levels were associated
with progression of RA and were also shown to correlate
with RA activity [18]. Moreover, elevated levels of C1M
were found in OA patients with higher CRP [15] and
CRPM levels [16]. It seems that inflammation is import-
ant in disease pathology in a subset of the OA popula-
tion; however, the pathology of this subset is not well
described and few longitudinal analyses of these patients
have been presented [19, 20].
Due to a general lack of consistent evidence, differ-
ences between the populations studied (clinical trials vs.
population-based cohorts), and differences in sample
collection, future research is needed to validate the exist-
ing OA markers and to identify new candidates. The
aims of the present study were to explore the prognostic
value of two biomarkers of tissue-inflammation: C1M
and CPRM. In addition, we examined the extent to
which these two biomarkers could be considered to be
independent of well-known markers of uCTX-II and
COMP and demographic characteristics such as age, sex,
and body mass index (BMI) for incidence and progressionof radiographic OA in a large population of men and
women. Moreover, we investigated whether CRPM has




The Rotterdam Study (RS) is a population-based pro-
spective cohort study ongoing since 1990 to investigate
the occurrence and determinants of diseases in an aging
population [21]. The Rotterdam Study consists of three
subpopulations. The Rotterdam Study-I (RS-I) is the first
cohort of 7983 persons aged 55 years and older living in
the Ommoord district of Rotterdam in the Netherlands
[21]. The RS-II started in 2000 when 3011 participants
were recruited into the study when they became 55 years
of age or moved into the study district. In 2006, a fur-
ther extension of the cohort was initiated, the RS-III, in
which 3932 subjects, aged 45–54 years, were included.
The study has been approved by the institutional review
board (Medical Ethics Committee) of the Erasmus
Medical Center and by the review board of The
Netherlands Ministry of Health, Welfare and Sports and
all participants gave written informed consent.
Baseline measurements were obtained through a home
interview and visits to the research center for physical
examinations and laboratory assessments. Blood samples
were drawn by venous puncture and stored at –20 °C at
baseline. Weight-bearing anteroposterior radiographs of
the knee and hip were obtained at baseline and after
5 years of follow-up. Radiographs were acquired with
the knee extended and the patella in a central position.
Radiographs of the pelvis were obtained with both feet
in 10° internal rotation and the X-ray beam centered on
the umbilicus. The present study includes RS-II cohort’s
participants for whom knee and hip radiographs at base-
line and 5-year follow-up were available and scored.
Subjects without baseline (n = 114) and follow-up radio-
graphs (n = 1358), without informed consent (n = 1),
without all biomarker data (n = 187), and subjects with
AS (n = 2), with RA (n = 11), and with total joint replace-
ment (TJR) due to fracture (n = 3) were excluded from
the study. Therefore, out of 3011 participants, 1335 sub-
jects were included in the current study.
Outcome assessment
Radiographs were scored for the presence of a TJR and
OA of the hip and knee according to the Kellgren and
Lawrence (KL) score. Radiographic OA (which we refer
to here as OA) was defined as a KL score ≥2 of one or
both joints or a TJR [22–25]. In addition, we defined
TJR as grade 5. The incidence of knee and/or hip OA
was defined as a combination of KL <2 at baseline and
KL ≥2 at follow-up. As there is no consensus on the
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progression in one definition for the overall progression
of osteoarthritis. This was defined as an increase in the
KL score between baseline and follow-up of ≥1. In the
case of a baseline score of zero, overall progression was
defined as an increase of ≥2. Patients with scores of 4
and 5 at baseline were left out of the progression ana-
lysis. Controls were free of OA at the joint site studied
but were allowed to have OA at other joint sites. For ex-
ample, if knee OA was studied, controls had to be free of
knee OA but were allowed to have hip OA. In total OA
analyses, controls were free of both hip and knee OA.
Joint pain was determined to be present based on the
answer (yes/no) to the questions if participants had had
persistent joint pain and stiffness in the last 6 weeks.
Quantification of biomarkers
In order to ensure the reproducibility and performance
of the assays, three genuine urine or serum samples, in
addition to the kit controls, were added as quality con-
trols on each microtiter plate, and the entire plate was
rerun if any of the genuine controls were determined to
have a concentration >20 % of the predetermined value.
uCTX-II measurement
Subsequent to overnight fasting, urine samples were ob-
tained from all subjects at baseline and kept frozen at –
20 °C. Monoclonal antibody mAbF46, specific for CTX-II
fragments, was used in a competitive enzyme-linked im-
munosorbent assay (ELISA) (Immunodiagnostic Systems
Nordic, Copenhagen S, Denmark) following the instruc-
tions of the manufacturer. The concentration of uCTX-II
(in ng/l) was standardized to the total urine creatinine
(mmol/l), and the units for the corrected uCTX-II con-
centration are ng/mmol [7].
COMP measurement
Serum COMP (COMP®, AnaMar, Göteborg, Sweden)
were measured using enzyme-linked immunosorbent as-
says based on a monoclonal antibody.
CRPM, C1M measurements
Biomarkers were analyzed from fasting serum by Nordic
Bioscience, Herlev, Denmark. The markers were measured
by validated ELISAs applying neoepitope-specific mono-
clonal antibodies (Nordic Bioscience, Herlev, Denmark).
The technical data (reproducibility and stability) for the
assays are described in the published technical articles on
the assays. The technical data are available in the following
articles: C1M [17], and CRPM [16].
CRP measurement
High-sensitivity (hs)-CRP was measured using Rate Near
Infrared Particle Immunoassay (Immage ImmunochemistrySystem; Beckman Coulter, Brea, CA, USA). This method
can accurately measure protein concentrations from 0.2–
1440 mg/l with a within-run precision <5.0 %, a total pre-
cision <7.5 %, and a reliability coefficient of 0.995 [26].
Statistical analyses
Missing values of biomarkers [C1M: n = 39 (2.9 %); CRPM:
n = 38 (2.8 %); CTX-II: n = 116 (8.7 %); COMP: n = 12
(0.9 %); CRP: n = 35 (2.6 %)], BMI (n = 6, 0.4 %), alcohol in-
take (n = 6, 0.4 %), smoking status (n = 1, 0.08 %), educa-
tion (n = 20, 1.5 %), and diabetes (n = 5, 0.4 %) were
imputed based on a maximum likelihood estimation
method accounting for the correlation structure within the
data [27]. In all analyses, levels of markers were log10-
transformed to normalize their distributions. Standardized
scores (Z score) were made for continuous variables; there-
fore the odds ratio (OR) is expressed as percentage of
change per one standard deviation.
Pearson correlation coefficients were calculated to
evaluate the correlation between biomarkers. A logistic
regression model adjusted for confounding variables was
used to calculate OR and 95 % confidence interval (CI)
for incidence and overall progression of OA in relation
to each biomarker. Age, gender, BMI [weight (kg)/height
(m2)], and presence of radiographic OA were included
as confounding variables. The effect of diabetes, current
smoking (self-reported), educational level, and alcohol
intake (current, former, never) as potential confounding
variables were examined, but did not appreciably change
the risk estimates (less than 10 % change in the esti-
mates) and, therefore, were not included in the final
models. Moreover, through simultaneous modeling, we
investigated whether the biomarker findings are inde-
pendent of one another. Generalized estimating equation
(GEE) models were further used for a joint-based ana-
lysis of knees and hips to fit the models for correlations
between the right and left extremity in each individual.
Evidence of statistical interaction of biomarkers with sex
and age was evaluated by including cross-product inter-
action terms in the corresponding multivariable models.
We further evaluated the association between the bio-
markers and baseline joint pain among individuals with
OA at baseline. In order to assess the discriminating
power of the biochemical markers studied we generated
receiver operating characteristic (ROC) curves for each
model. Area under the curve (AUC) of the models in-
cluding age, sex, and BMI after adding joint pain, base-
line KL score, and the biomarkers were evaluated.
Statistical analyses were performed using SPSS (IBM
SPSS Statistics 21; IBM Corp., Armonk, NY, USA).
Results
The descriptive characteristics of study participants are
presented in Table 1. Our study population was slightly
Table 1 General characteristics of the study participants







No OA at follow-up,
n = 955
Female, n (%) 1694 (56) 743 (55.7) 144 (60.5) 195 (59.8) 519 (54.4)
Age* 65.2 (8.43) 63.1 (6.48) 66.4 (7.90) 66.02 (7.72) 62.13 (5.71)
Body mass index, kg/m2* 27.3 (4.23) 27.04 (3.85) 27.96 (4.11) 28.01 (4.29) 26.69 (3.65)
Current alcohol drinker, n (%) 2455 (81.5) 1146 (85.8) 205 (86.1) 277 (85) 822 (86.2)
Current smoking, n (%) 692 (23) 298 (22.3) 37 (15.5) 59 (18.1) 226 (23.7)
Low level of education, n (%) 424 (31.8) 999 (33.9) 74 (31.1) 103 (31.6) 298 (31.2)
Diabetes, n (%) 182 (6.0) 68 (5.1) 12 (5.0) 21 (6.4) 42 (4.4)
Knee pain, n (%) 725 (24.1) 328 (24.6) 96 (40.3) 128 (39.3) 185 (19.4)
Hip pain, n (%) 458 (15.2) 207 (15.5) 48 (20.2) 62 (19) 132 (13.8)
Knee OA, n (%) 339 (11.3) 185 (13.9) 185 (78.1) 185 (56.7) -
Hip OA, n (%) 141 (4.7) 68 (5.1) 68 (28.7) 68 (20.9) -
uCTX-II*, ng/mmol - 2.3 (0.23) 2.42 (0.27) 2.40 (0.26) 2.27 (0.22)
COMP*, U/L - 1.03 (0.10) 1.06 (0.10) 1.06 (0.10) 1.02 (0.10)
CRP*, mg/l - 0.02 (0.49) 0.07 (0.48) 0.12 (0.49) -0.02 (0.48)
CRPM*, ng/ml - 1.01 (0.18) 1.01 (0.18) 1.02 (0.18) 1.01 (0.17)
C1M*, ng/ml - 1.59 (0.17) 1.60 (0.18) 1.61 (0.18) 1.58 (0.17)
OA osteoarthritis, uCTX-II (urinary) type II collagen degradation, COMP cartilage oligomeric protein, CPR C-reactive protein, CRPM matrix metalloproteinase-dependent
degradation of CRP, C1M connective tissue type I collagen turnover
*Mean (SD); levels of biomarkers are log10-trasformed
Table 2 Pearson correlations between biomarkers
CRPM CRP COMP uCTX-II
C1M Correlation coefficient 0.330 0.580 -0.111 0.033
p value <0.0001 <0.0001 0.001 0.223
CRPM Correlation coefficient 0.248 -0.015 -0.004
p value <0.0001 0.598 0.896
CRP Correlation coefficient -0.104 -0.041
p value 0.0001 0.135
COMP Correlation coefficient 0.159
p value <0.0001
The correlations were adjusted for sex, age, and body mass index
CRPM matrix metalloproteinase-dependent degradation of CRP, CRP C-reactive
protein, COMP cartilage oligomeric protein, uCTX-II (urinary) type II collagen
degradation, C1M connective tissue type I collagen turnover
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hol than total population. OA cases at baseline and
follow-up were older, more obese and diabetic, and
smoked less than subjects who remained healthy at
follow-up time.
Baseline levels of most of the biomarkers were higher
in OA cases compared with subjects who remained free
of OA during follow-up. At baseline, there were 68 and
185 hip OA and knee OA cases, respectively. At 5-year
follow-up, 41 hips (32 new cases) and 111 knees (68 new
cases) with incident OA were identified. Overall progres-
sion of OA was found in 170 out of 1295 participants
who were eligible for OA progression analyses [knee OA
cases (n = 122) and/or hip OA cases (n = 53)].
Biomarkers levels were significantly correlated to BMI
and age except for uCTX-II with BMI (p = 0.37) and
CRPM with age (p = 0.54) (data not shown). Moreover,
there were significant differences in C1M (p = 0.003) and
uCTX-II levels (p <0.0001) between men and women. For
age, gender, and BMI-corrected data, it was found that
most of the biomarkers at baseline were significantly asso-
ciated with each other, with the highest correlation be-
tween CRP, CRPM, and C1M (Table 2). Urinary CTX-II
was not correlated to any of the inflammatory markers.
Incidence and progression analyses
We observed a significant increased risk for incident OA
with higher levels of uCTX-II, COMP, and CRP, whichall remained significant in the full model including all
markers and covariates (Table 3). Incident OA cases
showed a trend toward higher levels of CRPM at base-
line, but this did not reach significance level. Overall
progression of OA was associated with uCTX-II, COMP,
CRP, and CRPM levels. We found that the reported as-
sociations were independent of other biomarkers and
remained significant in the full models.
We stratified the analysis for incidence and progres-
sion according to the affected joint (knee and hip OA).
However, statistical power was limited per stratum lead-
ing to wider confidence limits and nonsignificant results
Table 3 Adjusted odds ratios (OR) and 95 % confidence
intervals (CI) from logistic regression models for incident and
progression of osteoarthritis (OA) in relation to biomarkers levels
Incidence of OA, n = 88/955† Progression of OA*, n = 170/1125‡
OR (95 % CI) p value OR (95 % CI) p value
uCTX-II 1.3 (1.0–1.7) 0.05 1.3 (1.1–1.5) 0.01
COMP 1.3 (1.1–1.6) 0.02 1.2 (1.04–1.5) 0.02
CRPM 1.2 (1.0–1.5) 0.07 1.3 (1.1–1.5) 0.01
C1M 1.1 (0.9–1.4) 0.23 1.1 (1.0–1.4) 0.10
CRP 1.5 (1.2–1.9) 0.0003 1.3 (1.1–1.5) 0.01
Full model
uCTX-II 1.3 (1.0–1.7) 0.05 1.3 (1.1–1.5) 0.01
COMP 1.3 (1.0–1.6) 0.03 1.2 (1.02–1.5) 0.03
CRPM 1.2 (0.9–1.5) 0.17 1.2 (1.01–1.5) 0.04
C1M 0.8 (0.6–1.1) 0.11 1.0 (0.8–1.2) 0.67
CRP 1.8 (1.3–2.4) 0.0003 1.3 (1.02–1.6) 0.03
OA incident defined as Kellgren and Lawrence (KL) ≥2 at knee and/or hip;
models were adjusted for age, sex, and body mass index; full models include
all biomarkers adjusted for age, sex, and body mass index
uCTX-II (urinary) type II collagen degradation, COMP cartilage oligomeric
protein, CRPM matrix metalloproteinase-dependent degradation of CRP,
C1M tissue type I collagen turnover, CRP C-reactive protein
†Case number/control number; ‡progressed/no-progressed; *additionally
adjusted for prevalent OA
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estimating equation analyses between incidence and pro-
gression of OA and individual or combined markers
showed similar results (data not shown).
Cross-sectional logistic regression analyses adjusted for
age, sex, and BMI between baseline OA status and CRPM
(OR = 1.0, 95 % CI = 0.8–1.1, p = 0.58), CRP (OR= 1.0,
95 % CI = 0.8–1.1, p = 0.70), and C1M (OR= 1.0, 95 % CI =
0.9–1.2, p = 0.92) levels showed no significant associations.
Moreover, we found a positive association, albeit non-
significant, between hip pain and CRPM levels (OR = 1.6,
p = 0.14), and between knee pain and CRP (OR = 1.3,
p = 0.10), and C1M levels (OR = 1.3, p = 0.09) adjusted
for age, sex, and BMI among OA baseline cases.
ROC curves of individual markers did not show higher
discriminative ability for C1M, CRPM, or CRP models
compared with uCTX-II in all OA analyses except a
slightly higher prediction ability of CRP for total OA and
hip OA incidence. ROC curves of the models including
demographic variables resulted in an AUC of 0.68 for
OA incidence (Fig. 1 and Additional file 2) and progres-
sion (Fig. 2 and Additional file 2). Adding the joint pain
variable to the models did not improve it, while subse-
quent addition of all biomarkers added considerable pre-
dictive value for OA. Doubtful baseline KL score of one
is the best predictor of future OA, even better than age,
gender and BMI alone.Discussion
We here evaluated two novel biomarkers for tissue in-
flammation (C1M and CRPM) for their ability to predict
incidence and progression of OA after 5 years of follow-
up in a population-based setting. We show that CRPM
is associated with incidence and progression of OA.
Moreover, CRPM had prognostic value for progression
of OA independent from uCTX-II and COMP. In the
full statistical model, CRPM and CRP proved to have
similar prognostic value as uCTX-II and COMP. To-
gether the biomarkers added significant prognostic
power to the known risk factors of age, gender and BMI.
To date, several studies have reported that levels of
uCTX-II and COMP are associated with OA and progres-
sion of OA, suggesting them as the most promising OA
biomarkers [5, 7–10, 28–31]. Consistently, we found that
uCTX-II and COMP levels were correlated with increased
risk and progression of OA, confirming our previous find-
ing among participants of RS-I [7, 10]. However, despite
substantial clinical investigations, none of these markers
have yet been proven to be of definite clinical value [32].
Different outcome measures and study designs as well as
limited sample size of these studies have resulted in
inadequate discriminating ability to differentiate between
individual patients and controls (diagnosis) or between pa-
tients with different disease severities (burden of disease),
and to predict prognosis in individuals with or without
osteoarthritis (prognosis) [33].
Our study showed that CRP levels were related to the
risk and progression of OA. In our previous study with
RS-I participants, an association between CRP levels and
incidence of hip OA was seen as well [12]. Data on hip
OA progression was limited in that review. A recent re-
view and meta-analysis of 32 studies showed no signifi-
cant associations between CRP levels and progression of
OA [defined as either exacerbation of joint space nar-
rowing (JSN) or TJR], while CRP levels were significantly
associated with pain and decreased physical function.
Therefore, it was suggested that CRP may be elevated in
OA patients, but probably plays a greater role in symp-
toms rather than radiographic changes in OA [14]. In
our study, we observed no significant associations be-
tween knee and hip pain and CRP levels among preva-
lent cases at baseline when controlled for BMI. It should
be noted that there was significant heterogeneity due to
the quality and methodology of the studies included in
the meta-analyses and the result should be regarded with
caution.
It has been shown that the CRPM level is elevated in
OA patients compared to the healthy adult reference
range, and that the inflammatory burden is independent
of disease severity (KL score) [15]. In our study, we ob-
served progression of OA to be associated with higher
levels of CRPM. Moreover, the association seemed to be
Fig. 1 ROC curves of the risk prediction models for incident osteoarthritis
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the role of systemic inflammation in OA etiology and
progression [14], however, CRPM, a degradation product
of CRP, and a possible biomarker of chronic tissue
inflammation, might point toward a local low-grade
inflammation to play a role in a subset of individuals
with OA. Our results suggest that this subset is more
prone to radiographic OA progression.
We observed no association between levels of C1M and
incidence and progression of OA in both biomarker-
specific and full models. The collagen biomarker C1M
was found to be higher in OA patients with an elevated
inflammatory burden as measured by high-sensitivity CRP
[15] and CRPM [16]. Previous analysis of C1M in RA has
shown that the biomarkers were associated with structural
progression measured by JSN [15]. Moreover, a recent
ex vivo experiment showed that under pro-inflammatory
conditions serological biomarkers C1M, MMP-mediated
degradation of collagen type III (C3M), and active MMP-3
may originate from the inflamed synovial membrane
(Kjelgaard-Petersen CF, Bay-Jansen AC, Christiansen T,Ladel C, Karsdal MA, Siebuhr AS. Novel synovitis bio-
markers: TNF-α and IL-1β include MMP-mediated
degradation of collagen type I and III and active MMP-3
and -9 in synovial membrane explants. 2014, Submitted).
Our study showed significant positive linear association
between C1M levels and CRPM, and CRP levels adjusted
for age, sex, and BMI among baseline OA cases (data not
shown). These findings illustrates that connective tissue
turnover in OA (i.e., C1M levels) is increased with inflam-
mation and, together with our findings of CRP and CRPM,
provide more support to the importance of local inflam-
mation in OA pathogenesis in a subgroup of patients.
Identification of subjects at a high risk of OA is neces-
sary for preventive strategies. Biochemical markers might
help in identification of subgroups of OA patients with
higher risk of progression. Age, gender, and BMI are
already rather strong predictors of OA risk and progres-
sion at older age in the population studied and in other
investigations [10]. In a previous study among participants
of RS-I, a prognostic model for incident knee OA was
developed based on clinical, genetic and biochemical
Fig. 2 ROC curves of the risk prediction models for osteoarthritis progression
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risk factors combined had a relatively low predictive value
for knee OA. In contrast, a model including doubtful
minor radiographic degenerative features (KL score = 1)
reached a good predictive value. Consistently, in our
study, baseline KL score of one was the best predictor of
future OA, and even better than age, gender and BMI
alone. Addition of well-established biochemical markers
together with tissue inflammation biomarkers added mod-
erate predictive value to most of our models. Moreover,
for the first time, we showed that a marker of MMP-
dependent inflammation is able to predict progression of
OA independent of established biomarkers uCTX-II and
COMP. Future investigations are needed to identify the
potential usefulness of the tissue inflammatory biomarkers
in OA prediction in a clinical setting.
Radiographic OA bears little relationship to the illness
characterized by joint pain and functional impairment
[35, 36]. Different factors (i.e., bone marrow lesions, joint
effusion, psychological factors, comorbidities) and mecha-
nisms of joint pain (i.e., nociceptive pain, neuropathicpain, and central pain sensitization) have been described
in OA patients [37, 38]. A recent study among OA pa-
tients showed the correlations between central pain mech-
anisms (temporal summation and pain modulation) and
CRPM, independently of age, gender, BMI, and hsCRP
[37]. Consistently, we found a positive association, albeit
nonsignificant, between hip pain and CRPM levels, and
between knee pain and CRP and C1M levels. These trends
support the role of inflammation as a possible underlying
mechanism of joint pain in OA, but more power is needed
to definitely prove this suggestion.
There were considerable correlations between different
markers reflecting turnover of cartilage (CTX-II, COMP,
and C1M) and inflammatory markers (CRP and CRPM).
Therefore, simultaneous modeling of several markers
could provide more insight into the role of individual
markers in OA progression. Moreover, due to the longitu-
dinal design of the study, we were able to assess the poten-
tial predictive value of the markers to predict disease risk
and progression. Controlling for confounder factors
including age, sex, BMI, smoking status, education, and
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ever, had some limitations that must be taken into ac-
count. First of all, biomarkers were only assessed in
baseline samples. Serial biomarker assessments could also
be very informative on the natural dynamics of each bio-
chemical marker and on disease status. Moreover, the bio-
marker contributions from OA need to be distinguished
from the contributions of normal and age-related bone
and cartilage turnover, and other conditions affecting the
biomarkers levels; this is currently a primary limitation for
all systemic (serum and urine) biomarker measures [33].
However, individuals with rheumatoid arthritis or other
inflammatory arthropathies were excluded from our ana-
lyses. Additionally, we adjusted the analyses for BMI and
age, two major factors which affect the biomarkers levels.
Second, OA definition was based on KL grades, which
conflate osteophytes, and JSN and some studies have
shown that biomarker associations can be different with
respect to these related but different features [39]. Third,
knee OA was defined using anteroposterior radiographs of
the knee. Therefore, patellofemoral joint OA was not
taken into account in the study. Moreover, uncontrolled
occurrence of misalignment of the medial tibial plateau
and central X-ray beam in standing anteroposterior radio-
graphs of the knee might result in an underestimation of
the rate and homogeneity of JSN in knee OA [40]. Fourth,
pain was assessed by questionnaire and not by more pre-
cise methods such as Western Ontario and McMaster
Universities Arthritis Index pain score or visual analog
scale. Fifth, controls were free of OA at the joint site stud-
ied but were allowed to have OA at other joint sites. For
example, if knee OA was studied, controls had to be free
of knee OA but were allowed to have hip OA. In addition,
the inference of the relevant relationships between serum
or urine biomarker concentrations and disease of specific
joints is complicated by the fact that our OA patients
might have disease in other joints such as hands or spine
joints. Sixth, several studies have suggested that risk fac-
tors for incidence of OA may be different from risk factors
for progression [41]. This could be due to heterogeneity in
OA structural pathology (e.g., bony proliferation versus
cartilage loss), limitations of imaging, which may result in
different sensitivities to the structural features, limited
sample size of the studies that examined the risk factors,
and that the risk factors may affect disease differently at
different disease stages [41]. Although we had a reason-
able sample size for total OA incidence and progression
analyses, the statistical power was limited to identify
which factors operate at different disease stages and for
analyses of OA phenotypes leading to wider confidence
limits. Finally, although we covered several confounding
variables, we could not exclude bias due to unmeasured
confounding factors as well as health-based selection bias
as we used a subset of RS-II participants who had follow-up data. These subjects were probably more mobile to
visit the center and survived in the follow-up period.
Conclusions
Our study confirmed that the uCTX-II and COMP con-
centrations are associated with incidence and progression
of radiographic OA. Moreover, we showed for the first
time that a MMP-dependent tissue-inflammation marker
predicts the risk of OA progression independent of estab-
lished biomarkers uCTX-II and COMP at the 5-year
follow-up. This indicates that inflammation is associated
with disease progression in OA and that inflammation has
pathological relevance in OA. Further prospective studies
are needed to confirm this association for OA.
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